Please login to the form below

Not currently logged in
Email:
Password:

Kurve launches nasal drug delivery blog

The first blog to address issues related to nasal drug delivery formulation, research, delivery and devices is launched by US nasal drug delivery specialist, Kurve Technology

The first blog to address issues related to nasal drug delivery formulation, research, delivery and devices has been launched by US nasal drug delivery specialist, Kurve Technology.

The blog can be found on www.nasaldrugdeliveryblog.com and invites scientists, researchers and pharmaceutical executives to exchange and comment on clinical research, recently-published journal articles, events and conferences and thought-provoking posts on systemic, topical and nose-to-brain delivery.

Non-promotional blog entries are authored by the executive team of Kurve Technology, as well as guest contributors.

Marc Giroux, CEO of Kurve Technology, said: ìOur aim was to create an online forum for open communication in the nasal delivery industry. Now academic researchers, pharmaceutical industry managers, and device professionals can interact every day rather then wait for the next conference or event. Pharmaceutical and trade media can also stay abreast of industry developments via the blog.î

7th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics